“…These live vaccines were then replaced by cell-cultured poxvirus vaccines (ACAM2000, CCSV), which still contained replicating virus. The cell-cultured vaccines were found to have similar safety concerns [36] , [37] , including, as previously noted, the occurrence of acute myocarditis and pericarditis, as well as the potential for local replication and onward transmission. MVA-BN was developed as a safer, nonreplicating vaccine in a liquid-frozen formulation administered by subcutaneous injection, rather than by skin scarification with a bifurcated needle.…”